Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study

被引:0
作者
Regan, Annette K. [1 ,2 ]
Sullivan, Sheena G. [2 ,3 ]
Arah, Onyebuchi A. [2 ,4 ,5 ,6 ,7 ]
机构
[1] Univ San Francisco, Sch Nursing & Hlth Profess, 480 S Batavia St, Orange, CA 96786 USA
[2] UCLA, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA
[3] Royal Melbourne Hosp, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia
[4] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia
[5] UCLA, Dept Stat & Data Sci, Los Angeles, CA USA
[6] UCLA, Pract Causal Inference Lab, Los Angeles, CA USA
[7] Aarhus Univ, Dept Publ Hlth, Res Unit Epidemiol, Aarhus, Denmark
关键词
Inactivated influenza vaccine; Miscarriage; Pregnancy; Vaccine safety; Maternal vaccination; PREGNANCY BIRTH-DEFECTS; SPONTANEOUS-ABORTION; PRETERM DELIVERY; SAFETY; OUTCOMES; IMMUNIZATION; H1N1PDM09; RECEIPT; WOMEN;
D O I
10.1016/j.vaccine.2024.126256
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Although numerous studies support the safety of influenza vaccination during pregnancy, fewer studies have evaluated the risk of miscarriage or considered the effect of prior immunization. Methods: Using national de-identified administrative claims data from the Optum Labs Data Warehouse, we conducted a claims-based cohort study of 117,626 pregnancies between January 2009 and December 2018. We identified pandemic A(H1N1)pdm09 and seasonal influenza vaccinations using CPT codes. Fetal loss was defined as miscarriage, medical termination, or stillbirth as identified by ICD-10-CM diagnostic codes. Cox proportional hazard models treating influenza vaccination as a time-varying exposure, weighted for loss-to-follow-up and stratified by baseline probability of vaccination, were used to model the risk of fetal loss by exposure to influenza vaccine. Results: About 31.4 % of the cohort had a record of influenza vaccination; 10.0 % were vaccinated before pregnancy only, 17.8 % during pregnancy only, and 3.6 % before and during pregnancy. The risk of miscarriage was 39 % lower among those vaccinated during pregnancy compared to unvaccinated (adjusted hazard ratio, aHR 0.61; 95 % CI 0.50, 0.74) and was similar for medical termination or stillbirth (HR 0.69; 95 % CI 0.45, 1.03 and aHR 0.99; 95 % CI 0.76, 1.30, respectively). Similar results were observed for women who received the vaccine before and during pregnancy. We observed little to no association between vaccination before pregnancy and risk of miscarriage (HR 0.98; 95 % CI 0.76, 1.26), medical termination (HR 1.02; 95 % CI 0.46, 2.24), or stillbirth (HR 1.14, 95 % CI 0.77, 1.69). Discussion: Influenza vaccination was not associated with an increased risk of fetal loss. These results support the safety of influenza vaccine administration even when administered before or early during pregnancy.
引用
收藏
页数:8
相关论文
共 43 条
  • [1] Using Insurance Claims Data to Identify and Estimate Critical Periods in Pregnancy: An Application to Antidepressants
    Ailes, Elizabeth C.
    Simeone, Regina M.
    Dawson, April L.
    Petersen, Emily E.
    Gilboa, Suzanne M.
    [J]. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2016, 106 (11) : 927 - 934
  • [2] [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
  • [3] Racial disparities in US maternal influenza vaccine uptake: Results from analysis of Pregnancy Risk Assessment Monitoring System (PRAMS) data, 2012-2015
    Arnold, Lauren D.
    Luong, Lan
    Rebmann, Terri
    Chang, Jen Jen
    [J]. VACCINE, 2019, 37 (18) : 2520 - 2526
  • [4] Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development
    Avalos, Lyndsay A.
    Ferber, Jeannette
    Zerbo, Ousseny
    Naleway, Allison L.
    Bulkley, Joanna
    Thompson, Mark
    Cragan, Janet
    Williams, Jennifer
    Odouli, Roxana
    Kauffman, Tia L.
    Ball, Sarah
    Shifflett, Pat
    Li, De-Kun
    [J]. VACCINE, 2020, 38 (10) : 2326 - 2332
  • [5] Pandemic A/H1N1 influenza vaccination during pregnancy: A comparative study using the EFEMERIS database
    Beau, A. B.
    Hurault-Delarue, C.
    Vidal, S.
    Guitard, C.
    Vayssiere, C.
    Petiot, D.
    Montastruc, J. L.
    Damase-Michel, C.
    Lacroix, I.
    [J]. VACCINE, 2014, 32 (11) : 1254 - 1258
  • [6] Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12
    Chambers, Christina D.
    Xu, Ronghui
    Mitchell, Allen A.
    [J]. VACCINE, 2017, 35 (40) : 5323 - 5324
  • [7] Safety of the 2010-11, 2011-12, 2012-13, and 2013-14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS
    Chambers, Christina D.
    Johnson, Diana L.
    Xu, Ronghui
    Luo, Yunjun J.
    Louik, Carol
    Mitchell, Allen A.
    Schatz, Michael
    Jones, Kenneth L.
    [J]. VACCINE, 2016, 34 (37) : 4443 - 4449
  • [8] Risks and safety of pandemic h1n1 influenza vaccine in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants
    Chambers, Christina D.
    Johnson, Diana
    Xu, Ronghui
    Luo, Yunjun
    Louik, Carol
    Mitchell, Allen A.
    Schatz, Michael
    Jones, Kenneth L.
    [J]. VACCINE, 2013, 31 (44) : 5026 - 5032
  • [9] Internal validation of gestational age estimation algorithms in health-care databases using pregnancies conceived through fertility procedures
    Chiu, Yu-Han
    Huybrechts, Krista F.
    Zhu, Yanmin
    Straub, Loreen
    Bateman, Brian T.
    Logan, Roger
    Hernandez-Diaz, Sonia
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2024, 193 (08) : 1168 - 1175
  • [10] Development and Validation of ICD-10-CM-based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant Outcomes
    Chomistek, Andrea K.
    Phiri, Kelesitse
    Doherty, Michael C.
    Calderbank, Jenna F.
    Chiuve, Stephanie E.
    McIlroy, Brenda Hinman
    Snabes, Michael C.
    Enger, Cheryl
    Seeger, John D.
    [J]. DRUG SAFETY, 2023, 46 (02) : 209 - 222